8-K: Eledon Pharmaceuticals Reports Q3 2025 Results, Advances Tegoprubart

Eledon Pharmaceuticals announced its third quarter 2025 financial results and positive Phase 2 BESTOW trial data for tegoprubart, supporting its advancement into Phase 3 development for kidney transplant rejection prevention.

Summary

• Reported third quarter 2025 operating and financial results.
• Phase 2 BESTOW trial data for tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus.
• Kidney function, as measured by estimated glomerular filtration rate (eGFR), was approximately 69 mL/min/1.732 at 12-months for participants in the tegoprubart treatment arm (n=51).
• Plans to advance tegoprubart into Phase 3 development for kidney transplantation following discussions with regulators.
• Completed an underwritten public offering on November 13, 2025, resulting in total gross proceeds of $57.5 million and net proceeds of approximately $53.6 million.
• Cash, cash equivalents, and short-term investments totaled $93.4 million as of September 30, 2025, compared to $140.2 million as of December 31, 2024.
• Research and development (R&D) expenses for the third quarter of 2025 were $15.0 million, down from $16.5 million for the comparable period in 2024.
• General and administrative expenses for the third quarter of 2025 were $4.1 million, up from $4.0 million for the comparable period in 2024.
• Net loss for the third quarter of 2025 was $17.5 million, or $0.21 per basic common share, compared to a net income of $77.0 million, or $1.05 per basic common share, for the comparable period in 2024.
• Net income in the third quarter of 2024 included a non-cash gain of $96.4 million related to changes in the fair value of warrant liabilities; excluding this, a net loss of $19.5 million would have been recorded for Q3 2024.

Sentiment

Score: 7

Explanation: The company reported positive Phase 2 clinical trial results for tegoprubart, demonstrating a favorable safety profile and efficacy in kidney transplant rejection prevention, which supports advancement to Phase 3. A significant capital raise of $57.5 million strengthens the balance sheet to fund these programs. While the company continues to report a net loss and burn cash, this is expected for a clinical-stage biotech, and the operational net loss actually improved compared to the prior year's adjusted figures.

Positives

• Phase 2 BESTOW trial demonstrated tegoprubart's excellent efficacy and safety profile, substantially reducing common toxicities of standard-of-care immunosuppressive therapies like tacrolimus.
• Kidney function (eGFR) of approximately 69 mL/min/1.732 at 12-months in the tegoprubart treatment arm (n=51) is a positive indicator.
• Data supports advancement of tegoprubart into Phase 3 development for kidney transplant rejection prevention.
• Strengthened balance sheet with $57.5 million gross proceeds ($53.6 million net) from a recent public offering, enhancing ability to advance transplantation programs.
• Research and development (R&D) expenses decreased to $15.0 million in Q3 2025 from $16.5 million in Q3 2024.

Negatives

• Cash, cash equivalents, and short-term investments decreased to $93.4 million as of September 30, 2025, from $140.2 million as of December 31, 2024.
• Reported a net loss of $17.5 million ($0.21 per basic common share) for Q3 2025, compared to a net income of $77.0 million ($1.05 per basic common share) in Q3 2024.
• The Q3 2024 net income was significantly boosted by a non-cash gain of $96.4 million from warrant liabilities, indicating a substantial operational loss in the prior year as well (adjusted net loss of $19.5 million for Q3 2024).
• Accumulated deficit increased to $(390,756) thousand as of September 30, 2025, from $(355,586) thousand as of December 31, 2024.

Risks

• Short operating history and shifts in business strategy.
• Operating losses since inception.
• Need for additional funding to develop lead drug candidate and ability to secure it on acceptable terms or at all.
• Impact of common stock issuances, including potential dilution or stock price decline.
• Ability to successfully develop product candidates.
• Unfavorable global economic and financial market conditions.
• Regulatory environment of the business and ability to obtain required regulatory approvals.
• Results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials.
• Delays or difficulties in enrollment of patients in clinical trials.
• Ability to attract and retain executives and key employees.
• Legislation of the pharmaceutical and healthcare industries.
• Cybersecurity and data privacy risks.
• Ability of products to achieve marketing approval.
• Competition in the industry.
• Ability to obtain insurance coverage.
• Dependence on contract research organizations.
• Ability to protect intellectual property.
• Public health crises.
• Ability to establish and maintain proper and effective internal control over financial reporting.

Future Outlook

Eledon Pharmaceuticals plans to advance tegoprubart into Phase 3 development for kidney transplantation following discussions with regulators on study design and data requirements. The company anticipates enrolling the final three patients in the islet cell transplantation study in Q4 2025, receiving FDA guidance on Phase 3 kidney trial design in 2026, initiating the Phase 3 kidney trial in 2026, reporting long-term data from Phase 1 and 2 BESTOW studies in 2026, reporting data from nine patients in the islet cell transplantation study in 2026, and receiving FDA regulatory guidance for islet cell and xenotransplantation market path in 2026.

Management Comments

• "The results from our Phase 2 BESTOW trial demonstrated tegoprubart's excellent efficacy and safety, importantly avoiding many of the long-term toxicities commonly seen with current standard-of-care immunosuppressive therapies." David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon.
• "Further, the proceeds from our recent financing enhance our ability to advance tegoprubart's programs in kidney transplantation, islet cell transplantation, and xenotransplantation, addressing critical unmet needs in transplant medicine." David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon.

Industry Context

Eledon Pharmaceuticals operates in the clinical-stage biotechnology sector, focusing on immune-modulating therapies, specifically anti-CD40L antibodies. The development of tegoprubart for preventing organ rejection in kidney transplants and its potential in islet cell and xenotransplantation addresses significant unmet needs in transplant medicine, an area where current standard-of-care immunosuppressants like tacrolimus are effective but carry substantial toxicity burdens (metabolic, neurologic, cardiovascular). A therapy that can reduce these toxicities while maintaining efficacy would represent a significant advancement and potential new standard of care, positioning Eledon favorably against existing treatments and other companies developing novel immunosuppressants.

Comparison to Industry Standards

• Tegoprubart's Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus, the current standard-of-care immunosuppressant. This suggests a potential improvement over existing treatments by mitigating severe side effects.
• The reported kidney function (eGFR) of approximately 69 mL/min/1.732 at 12-months for tegoprubart-treated patients (n=51) will need to be benchmarked against long-term outcomes of tacrolimus-based regimens and other investigational therapies in similar patient populations to fully assess its comparative efficacy.
• The advancement to Phase 3 development indicates that tegoprubart has met key clinical milestones, aligning with the typical progression for promising drug candidates in the biotechnology industry.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical trial results and advancement to Phase 3, but also dilution from the recent public offering and continued operational losses. The capital raise provides runway, reducing immediate financing risk.
• Patients (Kidney Transplant, Type 1 Diabetes, Xenotransplantation): Hope for a new, potentially safer and more effective treatment for organ rejection and other life-threatening conditions, reducing toxicities associated with current therapies.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.
• Regulatory Authorities (FDA): Will be engaged in discussions regarding Phase 3 trial design and future market pathways for tegoprubart.

Next Steps

• Enroll final three patients with Type 1 diabetes in the investigator-led clinical study evaluating tegoprubart in islet cell transplantation in Q4 2025.
• Receive U.S. Food & Drug Administration (FDA) guidance on the Phase 3 trial design for kidney transplantation in 2026.
• Initiate a Phase 3 trial in kidney transplantation in 2026.
• Report long-term data from the Phase 1 and Phase 2 BESTOW studies in kidney transplantation in 2026.
• Report data from nine patients in the investigator-led islet cell transplantation study in 2026.
• Receive FDA regulatory guidance on path to market for islet cell transplantation & xenotransplantation in 2026.

Key Dates

Recommendation

Eledon Pharmaceuticals has delivered strong Phase 2 clinical data for tegoprubart, demonstrating a favorable safety profile and efficacy that could position it as a superior alternative to current standard-of-care immunosuppressants. The successful $57.5 million capital raise provides crucial funding for advancing tegoprubart into Phase 3 trials and other transplantation programs. While the company continues to incur operational losses, which is typical for a clinical-stage biotech, the Q3 2025 operational net loss showed a slight improvement over the prior year. The significant dilution from the recent offering and the inherent risks associated with late-stage clinical development and regulatory approval warrant a cautious approach. Existing investors should hold to monitor Phase 3 progress and regulatory interactions, while new investors might consider holding off until further de-risking occurs, balancing the significant upside potential with the substantial execution risks.

Keywords

Eledon Pharmaceuticals, ELDN, tegoprubart, kidney transplant, organ rejection, immunosuppression, Phase 2 BESTOW trial, Phase 3 development, islet cell transplantation, xenotransplantation, biotechnology, clinical stage, CD40L antibody, financial results, Q3 2025, public offering, R&D expenses, net loss